title: [Drug interactions of midazolam].
abstract: Midazolam is a short-acting benzodiazepine with a short half life (1.5-2.5 h) due to intense biotransformation by liver monooxygenases. Anecdotal clinical reports have mentioned a wide interpatient variability in its duration of action. We investigated by in vitro screening factors that could interfere with the rate of midazolam biotransformation (drug-drug interactions). Metabolite production (1'-and 4-OH-midazolam) was monitored in human liver microsomes. Midazolam hydroxylations are inhibited by several drugs (i.e. erythromycin, phenothiazine-type neuroleptics, cyclosporine). The clinical relevance of these drug interactions is illustrated by the example of a patient treated with amiodarone, erythromycin and midazolam during anesthesia. Midazolam-induced sleep lasted about 6 days due to inhibition of its biotransformation by concomitant drug treatment.
authors.affiliation: Division de Pharmacologie clinique, Hôpital cantonal universitaire, Genève.
authors.forename: M P
authors.initials: MP
authors.lastname: Gascon
authors.forename: P
authors.initials: P
authors.lastname: Dayer
authors.forename: F
authors.initials: F
authors.lastname: Waldvogel
mesh_terms: D001711:Biotransformation; D004347:Drug Interactions; D006801:Humans; D006900:Hydroxylation; D066298:In Vitro Techniques; D008297:Male; D008862:Microsomes, Liver / Q000032:analysis; D008874:Midazolam / Q000031:analogs & derivatives / Q000032:analysis / Q000493:pharmacokinetics*; D008875:Middle Aged
chemical_list: C040081:1-hydroxymethylmidazolam; D008874:Midazolam
vernacular_title: Les interactions médicamenteuses du midazolam.